So IMU has spent $500M and they should charge the patient for the clinical trial lol. Who is saying a T/O at current price???? You clearly don't know how biotech start-up stock work. IMU are already seeing efficacy early in Ph1 which is very rare as they are about demonstrating safety to advance the IP development to the next stage with increase dosage to determine OBD to allow the best efficacy chance. BP do T/O of IP usually in Ph3 clinical trial because that's the stage were efficacy is usually seen in IP and also fail due to lack of efficacy.......
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)